LadRx P/FCF

Que fait LadRx ? LadRx Corp, with ticker LADX and ISIN US2328287071, is a biotechnology company headquartered in Los Angeles, United States. The company has 2 employees and went public on November 10, 1986. Its website is http://www.cytrx.com/. LadRx Corp operates within the Health Care sector, specifically in the Biotechnology industry. The company's activities include the discovery, research, and clinical development of anti-cancer drug candidates. It focuses on aldoxorubicin, a modified version of doxorubicin, for clinical development. The company is involved in Phase III trials for aldoxorubicin as a treatment for soft tissue sarcoma in patients whose tumors have progressed after chemotherapy. Additionally, LadRx Corp is conducting Phase IIb trials for aldoxorubicin in small cell lung cancer, Phase II trials for HIV-related Kaposi's sarcoma, and Phase II trials for late-stage glioblastoma. The company also has Phase Ib trials combining aldoxorubicin with ifosfamide for soft tissue sarcoma and with gemcitabine for metastatic solid tumors. LadRx Corp is developing DK049, an anti-cancer drug conjugate utilizing its LADR technology, in pre-clinical stages. The company's website and public filings provide further details on its operations and clinical trials. LadRx est l'une des entreprises les plus populaires sur Eulerpool.